DE69512816T2 - Oxopyridylchinoxalin Derivate - Google Patents
Oxopyridylchinoxalin DerivateInfo
- Publication number
- DE69512816T2 DE69512816T2 DE69512816T DE69512816T DE69512816T2 DE 69512816 T2 DE69512816 T2 DE 69512816T2 DE 69512816 T DE69512816 T DE 69512816T DE 69512816 T DE69512816 T DE 69512816T DE 69512816 T2 DE69512816 T2 DE 69512816T2
- Authority
- DE
- Germany
- Prior art keywords
- nitro
- lower alkyl
- hydrogen
- halogen
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 100
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 57
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 46
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 43
- 150000002367 halogens Chemical class 0.000 claims abstract description 43
- 239000001257 hydrogen Substances 0.000 claims abstract description 43
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 28
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims abstract description 19
- 125000004953 trihalomethyl group Chemical group 0.000 claims abstract description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 18
- 230000002461 excitatory amino acid Effects 0.000 claims abstract description 18
- 239000003257 excitatory amino acid Substances 0.000 claims abstract description 18
- 125000001424 substituent group Chemical group 0.000 claims abstract description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 17
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 15
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 10
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 39
- 150000002431 hydrogen Chemical group 0.000 claims description 21
- 210000002569 neuron Anatomy 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000018899 Glutamate Receptors Human genes 0.000 claims description 8
- 108010027915 Glutamate Receptors Proteins 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000006957 competitive inhibition Effects 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract description 20
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract description 20
- 102000003678 AMPA Receptors Human genes 0.000 abstract description 17
- 108090000078 AMPA Receptors Proteins 0.000 abstract description 17
- 230000027455 binding Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 abstract description 5
- 108020003175 receptors Proteins 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 57
- 229910052799 carbon Inorganic materials 0.000 description 54
- 229910052757 nitrogen Inorganic materials 0.000 description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000013078 crystal Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 238000002844 melting Methods 0.000 description 30
- 230000008018 melting Effects 0.000 description 30
- 238000000921 elemental analysis Methods 0.000 description 27
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 23
- 239000004471 Glycine Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000000354 decomposition reaction Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 229940125890 compound Ia Drugs 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 235000006408 oxalic acid Nutrition 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 239000005457 ice water Substances 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- MFWBPQYSXPQJNB-UHFFFAOYSA-N 6-nitro-7-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C=C1 MFWBPQYSXPQJNB-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000003710 cerebral cortex Anatomy 0.000 description 6
- MSVAVCLZHVHHLY-UHFFFAOYSA-N 6-fluoro-7-nitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(F)=C2 MSVAVCLZHVHHLY-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- QTTWTDXNFGFBJP-UHFFFAOYSA-N 1-(3-amino-4-nitrophenyl)pyridin-4-one Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2C=CC(=O)C=C2)=C1 QTTWTDXNFGFBJP-UHFFFAOYSA-N 0.000 description 3
- MAWSJHLAXDFKPJ-UHFFFAOYSA-N 1-(4,5-diamino-2-fluorophenyl)pyridin-4-one Chemical compound C1=C(N)C(N)=CC(F)=C1N1C=CC(=O)C=C1 MAWSJHLAXDFKPJ-UHFFFAOYSA-N 0.000 description 3
- QQFFGTNLOQBNOS-UHFFFAOYSA-N 1-(5-amino-2-chloro-4-nitrophenyl)pyridin-4-one Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2C=CC(=O)C=C2)=C1Cl QQFFGTNLOQBNOS-UHFFFAOYSA-N 0.000 description 3
- KWGVCRUKKMHAQO-UHFFFAOYSA-N 1-(5-amino-2-fluoro-4-nitrophenyl)pyridin-4-one Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2C=CC(=O)C=C2)=C1F KWGVCRUKKMHAQO-UHFFFAOYSA-N 0.000 description 3
- CESXUQCTMRUHKU-UHFFFAOYSA-N 1-[4,5-diamino-2-(trifluoromethyl)phenyl]pyridin-4-one Chemical compound C1=C(N)C(N)=CC(N2C=CC(=O)C=C2)=C1C(F)(F)F CESXUQCTMRUHKU-UHFFFAOYSA-N 0.000 description 3
- JARSLSYKEADGBT-UHFFFAOYSA-N 4,5-diamino-2-(4-oxopyridin-1-yl)benzonitrile Chemical compound C1=C(N)C(N)=CC(C#N)=C1N1C=CC(=O)C=C1 JARSLSYKEADGBT-UHFFFAOYSA-N 0.000 description 3
- ROHIFHYSDLQFBK-UHFFFAOYSA-N 4-amino-5-nitro-2-(4-oxopyridin-1-yl)benzonitrile Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2C=CC(=O)C=C2)=C1C#N ROHIFHYSDLQFBK-UHFFFAOYSA-N 0.000 description 3
- OEOUFQKICIKUJU-UHFFFAOYSA-N 4-amino-n,n-dimethyl-5-nitro-2-(4-oxopyridin-1-yl)benzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC([N+]([O-])=O)=C(N)C=C1N1C=CC(=O)C=C1 OEOUFQKICIKUJU-UHFFFAOYSA-N 0.000 description 3
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 description 3
- RMGZAIUQHFFYAJ-UHFFFAOYSA-N 6-chloro-7-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound ClC1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C=C1 RMGZAIUQHFFYAJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 150000003252 quinoxalines Chemical class 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- WMOUOHINJJJCLE-UHFFFAOYSA-N 1-(3,4-diaminophenyl)pyridin-4-one Chemical compound C1=C(N)C(N)=CC=C1N1C=CC(=O)C=C1 WMOUOHINJJJCLE-UHFFFAOYSA-N 0.000 description 2
- VGDLTOHEPGEBEG-UHFFFAOYSA-N 1-(4,5-diamino-2-chlorophenyl)pyridin-4-one Chemical compound C1=C(N)C(N)=CC(Cl)=C1N1C=CC(=O)C=C1 VGDLTOHEPGEBEG-UHFFFAOYSA-N 0.000 description 2
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 2
- FDBNJUFYZBIJJK-UHFFFAOYSA-N 2,3-dioxo-7-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-6-carbonitrile Chemical compound C1=CC(=O)C=CN1C(C(=C1)C#N)=CC2=C1NC(=O)C(=O)N2 FDBNJUFYZBIJJK-UHFFFAOYSA-N 0.000 description 2
- YUWOLBZMQDGRFV-UHFFFAOYSA-N 3-nitro-1h-pyridin-4-one Chemical compound [O-][N+](=O)C1=CNC=CC1=O YUWOLBZMQDGRFV-UHFFFAOYSA-N 0.000 description 2
- KOWSJXPHKYVDKX-UHFFFAOYSA-N 4,5-diamino-n,n-dimethyl-2-(4-oxopyridin-1-yl)benzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC(N)=C(N)C=C1N1C=CC(=O)C=C1 KOWSJXPHKYVDKX-UHFFFAOYSA-N 0.000 description 2
- RWVIMCIPOAXUDG-UHFFFAOYSA-N 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C([N+]([O-])=O)=C2 RWVIMCIPOAXUDG-UHFFFAOYSA-N 0.000 description 2
- VWTYVSSTLNNPFS-UHFFFAOYSA-N 6-(1h-imidazol-2-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1C1=NC=CN1 VWTYVSSTLNNPFS-UHFFFAOYSA-N 0.000 description 2
- KDMABXHBRIUHQJ-UHFFFAOYSA-N 6-(3-chloro-4-oxopyridin-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C(Cl)=C1 KDMABXHBRIUHQJ-UHFFFAOYSA-N 0.000 description 2
- PKFYNEHOXBSWEM-UHFFFAOYSA-N 6-(3-fluoro-4-oxopyridin-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C(F)=C1 PKFYNEHOXBSWEM-UHFFFAOYSA-N 0.000 description 2
- REKLDMCLTRVKIC-UHFFFAOYSA-N 6-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound C1=CC(=O)C=CN1C1=CC=C(NC(=O)C(=O)N2)C2=C1 REKLDMCLTRVKIC-UHFFFAOYSA-N 0.000 description 2
- NZMHNPPXSMZZBX-UHFFFAOYSA-N 6-fluoro-7-nitro-4-propyl-1h-quinoxaline-2,3-dione Chemical compound FC1=C([N+]([O-])=O)C=C2NC(=O)C(=O)N(CCC)C2=C1 NZMHNPPXSMZZBX-UHFFFAOYSA-N 0.000 description 2
- ZPZQQZKACASZJU-UHFFFAOYSA-N 7-nitro-6-(4-oxopyridin-1-yl)-4-propyl-1h-quinoxaline-2,3-dione Chemical compound [O-][N+](=O)C=1C=C2NC(=O)C(=O)N(CCC)C2=CC=1N1C=CC(=O)C=C1 ZPZQQZKACASZJU-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000004381 Choline salt Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000019417 choline salt Nutrition 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- -1 nitronium tetrafluoroborate Chemical compound 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- OECSGKJNSQDODP-UHFFFAOYSA-N 1,4-dihydroquinoline-2,3-dione Chemical class C1=CC=C2NC(=O)C(=O)CC2=C1 OECSGKJNSQDODP-UHFFFAOYSA-N 0.000 description 1
- UWNYJWYGXJMFKZ-UHFFFAOYSA-N 1,4-dihydroxy-6-nitro-7-(4-oxopyridin-1-yl)quinoxaline-2,3-dione Chemical compound [O-][N+](=O)C=1C=C2N(O)C(=O)C(=O)N(O)C2=CC=1N1C=CC(=O)C=C1 UWNYJWYGXJMFKZ-UHFFFAOYSA-N 0.000 description 1
- IMSAOCNUVNHTPC-UHFFFAOYSA-N 1-[5-amino-4-nitro-2-(trifluoromethyl)phenyl]pyridin-4-one Chemical compound C1=C([N+]([O-])=O)C(N)=CC(N2C=CC(=O)C=C2)=C1C(F)(F)F IMSAOCNUVNHTPC-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- YKCQWIYRLMNGMO-UHFFFAOYSA-N 3,5-dichloro-1h-pyridin-4-one Chemical compound OC1=C(Cl)C=NC=C1Cl YKCQWIYRLMNGMO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NKEYLLFRPHHBOQ-UHFFFAOYSA-N 3-chloro-1h-pyridin-4-one Chemical compound OC1=CC=NC=C1Cl NKEYLLFRPHHBOQ-UHFFFAOYSA-N 0.000 description 1
- HTXNVGYNXOGIQZ-UHFFFAOYSA-N 3-fluoro-1h-pyridin-4-one Chemical compound FC1=CNC=CC1=O HTXNVGYNXOGIQZ-UHFFFAOYSA-N 0.000 description 1
- FSGTULQLEVAYRS-UHFFFAOYSA-N 4,5-dichloro-2-nitroaniline Chemical compound NC1=CC(Cl)=C(Cl)C=C1[N+]([O-])=O FSGTULQLEVAYRS-UHFFFAOYSA-N 0.000 description 1
- QDNOBTKJPANVQD-UHFFFAOYSA-N 4-amino-2-chloro-5-nitrobenzonitrile Chemical compound NC1=CC(Cl)=C(C#N)C=C1[N+]([O-])=O QDNOBTKJPANVQD-UHFFFAOYSA-N 0.000 description 1
- JVVVVRRPJFVYJJ-UHFFFAOYSA-N 4-amino-2-chloro-n,n-dimethyl-5-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC([N+]([O-])=O)=C(N)C=C1Cl JVVVVRRPJFVYJJ-UHFFFAOYSA-N 0.000 description 1
- BGKFPRIGXAVYNX-UHFFFAOYSA-N 5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid Chemical compound ClC1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 BGKFPRIGXAVYNX-UHFFFAOYSA-N 0.000 description 1
- AAMCWLIPRMIPBN-UHFFFAOYSA-N 5-chloro-2-nitro-4-(trifluoromethyl)aniline Chemical compound NC1=CC(Cl)=C(C(F)(F)F)C=C1[N+]([O-])=O AAMCWLIPRMIPBN-UHFFFAOYSA-N 0.000 description 1
- ZCWXYZBQDNFULS-UHFFFAOYSA-N 5-chloro-2-nitroaniline Chemical compound NC1=CC(Cl)=CC=C1[N+]([O-])=O ZCWXYZBQDNFULS-UHFFFAOYSA-N 0.000 description 1
- VRJKEIWZSOHDOH-UHFFFAOYSA-N 5-chloro-4-fluoro-2-nitroaniline Chemical compound NC1=CC(Cl)=C(F)C=C1[N+]([O-])=O VRJKEIWZSOHDOH-UHFFFAOYSA-N 0.000 description 1
- NODLAJFHJPBJSL-UHFFFAOYSA-N 6-(3,5-dichloro-4-oxopyridin-1-yl)-7-nitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=C(Cl)C(=O)C(Cl)=C1 NODLAJFHJPBJSL-UHFFFAOYSA-N 0.000 description 1
- MKCFKABSQKMCAR-UHFFFAOYSA-N 6-(4-oxopyridin-1-yl)-7-(trifluoromethyl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound FC(F)(F)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C=C1 MKCFKABSQKMCAR-UHFFFAOYSA-N 0.000 description 1
- RGYRJZRHYICFBC-UHFFFAOYSA-N 6-fluoro-7-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound FC1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C=C1 RGYRJZRHYICFBC-UHFFFAOYSA-N 0.000 description 1
- AZTQVUDITUJBEE-UHFFFAOYSA-N 6-nitro-7-(3-nitro-4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-2,3-dione Chemical compound [O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C([N+]([O-])=O)=C1 AZTQVUDITUJBEE-UHFFFAOYSA-N 0.000 description 1
- NSVYZSUYFUVVBI-UHFFFAOYSA-N 7-nitro-6-(3-nitro-4-oxopyridin-1-yl)-4-propyl-1h-quinoxaline-2,3-dione Chemical compound [O-][N+](=O)C=1C=C2NC(=O)C(=O)N(CCC)C2=CC=1N1C=CC(=O)C([N+]([O-])=O)=C1 NSVYZSUYFUVVBI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- SYGOKCVZUFVABC-SCSAIBSYSA-N N[C@@H](C(=O)O)CCCP(=O)=O Chemical compound N[C@@H](C(=O)O)CCCP(=O)=O SYGOKCVZUFVABC-SCSAIBSYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RUKCJUBTRDGPCC-UHFFFAOYSA-N acetic acid;acetyl acetate Chemical compound CC(O)=O.CC(=O)OC(C)=O RUKCJUBTRDGPCC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- VOZNGRHMRNVXJG-UHFFFAOYSA-N methyl 4-cyano-3-[(3,5-dinitrobenzoyl)amino]-1,5-dimethylpyrrole-2-carboxylate Chemical compound N#CC1=C(C)N(C)C(C(=O)OC)=C1NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VOZNGRHMRNVXJG-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- JOMIWWCFFZBIAU-UHFFFAOYSA-N n,n-dimethyl-2,3-dioxo-7-(4-oxopyridin-1-yl)-1,4-dihydroquinoxaline-6-sulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CC(=O)C=C1 JOMIWWCFFZBIAU-UHFFFAOYSA-N 0.000 description 1
- AOAOGMPDWVBLQE-UHFFFAOYSA-N n,n-dimethyl-2,3-dioxo-7-(4-oxopyridin-1-yl)quinoxaline-6-sulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC2=NC(=O)C(=O)N=C2C=C1N1C=CC(=O)C=C1 AOAOGMPDWVBLQE-UHFFFAOYSA-N 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7090994 | 1994-04-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69512816D1 DE69512816D1 (de) | 1999-11-25 |
| DE69512816T2 true DE69512816T2 (de) | 2000-04-27 |
Family
ID=13445121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69512816T Expired - Fee Related DE69512816T2 (de) | 1994-04-08 | 1995-04-07 | Oxopyridylchinoxalin Derivate |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5677305A (enExample) |
| EP (1) | EP0676397B1 (enExample) |
| KR (1) | KR100363003B1 (enExample) |
| CN (1) | CN1044241C (enExample) |
| AT (1) | ATE185806T1 (enExample) |
| AU (1) | AU688459B2 (enExample) |
| CA (1) | CA2146478A1 (enExample) |
| DE (1) | DE69512816T2 (enExample) |
| DK (1) | DK0676397T3 (enExample) |
| ES (1) | ES2140620T3 (enExample) |
| GR (1) | GR3032406T3 (enExample) |
| HU (1) | HUT72064A (enExample) |
| TW (1) | TW300894B (enExample) |
| ZA (1) | ZA952841B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU688459B2 (en) * | 1994-04-08 | 1998-03-12 | Shionogi & Co., Ltd. | Oxopyridinylquinoxaline derivative |
| AUPN842196A0 (en) * | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| HUP0002853A3 (en) * | 1997-09-01 | 2001-12-28 | Kyorin Seiyaku Kk | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them |
| EP1097927B1 (en) | 1998-06-01 | 2006-07-19 | Shionogi & Co., Ltd. | Cyanoiminoquinoxaline derivatives |
| ES2567133T3 (es) * | 2005-06-23 | 2016-04-20 | Array Biopharma, Inc. | Proceso para preparar compuestos de benzoimidazol |
| WO2010053757A1 (en) * | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| CN103664806B (zh) * | 2013-12-16 | 2016-06-29 | 山东汇海医药化工有限公司 | 一种n-乙酰乙酰基-6-甲氧基-7-氨基喹喔啉-2，3-二酮的制备方法 |
| EP3589616A1 (en) | 2017-02-28 | 2020-01-08 | Universitat Autònoma de Barcelona | (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies |
| WO2019161917A1 (en) | 2018-02-23 | 2019-08-29 | Universitat Autonoma De Barcelona | 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies |
| WO2024083850A1 (en) | 2022-10-18 | 2024-04-25 | ETH Zürich | Electrocatalyst |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE66149B1 (en) * | 1986-09-16 | 1995-12-13 | Novo Nordisk As | Quinoxaline compounds and their preparation and use |
| JP2635662B2 (ja) * | 1987-03-23 | 1997-07-30 | ノボ・ノルデイスク・アクツイエルスカブ | ヘテロ環状化合物，その製造方法及びその使用法 |
| NO179551C (no) * | 1987-11-10 | 1996-10-30 | Novo Nordisk As | Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser |
| DK160941C (da) * | 1988-06-28 | 1991-10-21 | Novo Nordisk As | Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar |
| US5153195A (en) * | 1988-12-22 | 1992-10-06 | Novo Nordisk A/S | Quinoxaline compounds and their preparation and use |
| DK715888D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| DK716188D0 (da) * | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| AU656154B2 (en) * | 1990-11-06 | 1995-01-27 | Astellas Pharma Inc. | Fused pyrazine derivative |
| JPH04193876A (ja) * | 1990-11-26 | 1992-07-13 | Sumitomo Chem Co Ltd | キノキザリン誘導体、その製造法およびそれを有効成分とする除草剤 |
| DK73091D0 (da) * | 1991-04-22 | 1991-04-22 | Novo Nordisk As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| JPH06228112A (ja) * | 1993-02-05 | 1994-08-16 | Yamanouchi Pharmaceut Co Ltd | （１ｈ，４ｈ）キノキサリン誘導体 |
| AU688459B2 (en) * | 1994-04-08 | 1998-03-12 | Shionogi & Co., Ltd. | Oxopyridinylquinoxaline derivative |
-
1995
- 1995-04-05 AU AU16256/95A patent/AU688459B2/en not_active Ceased
- 1995-04-06 CA CA002146478A patent/CA2146478A1/en not_active Abandoned
- 1995-04-06 ZA ZA952841A patent/ZA952841B/xx unknown
- 1995-04-07 US US08/418,196 patent/US5677305A/en not_active Expired - Fee Related
- 1995-04-07 AT AT95302326T patent/ATE185806T1/de not_active IP Right Cessation
- 1995-04-07 DK DK95302326T patent/DK0676397T3/da active
- 1995-04-07 HU HU9501026A patent/HUT72064A/hu unknown
- 1995-04-07 EP EP95302326A patent/EP0676397B1/en not_active Expired - Lifetime
- 1995-04-07 ES ES95302326T patent/ES2140620T3/es not_active Expired - Lifetime
- 1995-04-07 DE DE69512816T patent/DE69512816T2/de not_active Expired - Fee Related
- 1995-04-08 CN CN95105155A patent/CN1044241C/zh not_active Expired - Fee Related
- 1995-04-08 KR KR1019950008201A patent/KR100363003B1/ko not_active Expired - Fee Related
- 1995-04-08 TW TW084103375A patent/TW300894B/zh active
-
2000
- 2000-01-19 GR GR20000400103T patent/GR3032406T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GR3032406T3 (en) | 2000-05-31 |
| ZA952841B (en) | 1995-12-18 |
| CA2146478A1 (en) | 1995-10-09 |
| KR100363003B1 (ko) | 2003-02-11 |
| EP0676397A1 (en) | 1995-10-11 |
| AU688459B2 (en) | 1998-03-12 |
| DE69512816D1 (de) | 1999-11-25 |
| HUT72064A (en) | 1996-03-28 |
| CN1044241C (zh) | 1999-07-21 |
| EP0676397B1 (en) | 1999-10-20 |
| TW300894B (enExample) | 1997-03-21 |
| AU1625695A (en) | 1995-10-19 |
| US5677305A (en) | 1997-10-14 |
| DK0676397T3 (da) | 2000-04-03 |
| CN1123792A (zh) | 1996-06-05 |
| ES2140620T3 (es) | 2000-03-01 |
| HU9501026D0 (en) | 1995-06-28 |
| KR950032171A (ko) | 1995-12-20 |
| ATE185806T1 (de) | 1999-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69301618T2 (de) | Imidazol-Derivate, ihre Herstellung und Verwendung | |
| DE69132340T2 (de) | Kondensiertes pyrazinderivat | |
| DE69330715T2 (de) | Antitumor quinazoline | |
| DE69032550T2 (de) | Heteroarylamino- und Heteroaryloxypyridinamine und verwandte Verbindungen, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel | |
| DE60114153T2 (de) | Substituierte arylpyrazine | |
| DE69426422T2 (de) | Pyridazino-chinolin verbindungen | |
| DE69201068T2 (de) | Hydrazonderivate, ihre Herstellung und Verwendung. | |
| DE69521323T2 (de) | Quinoxalindion-nmda rezeptorantagonisten | |
| DE69512816T2 (de) | Oxopyridylchinoxalin Derivate | |
| DD231350A5 (de) | Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen | |
| DE68917708T2 (de) | Chinoxalin-Verbindungen, ihre Herstellung und Verwendung. | |
| DE69108156T2 (de) | Benzimidazolderivate, ihre Herstellung und ihre Verwendung. | |
| DE2815724C2 (enExample) | ||
| DE69713124T2 (de) | 1H-PYRIDO[3,4-b]INDOLCARBOXAMIDDERIVATE, IHRE HERSTELLUNG UND THERAPEUTISCHE VERWENDUNG | |
| DE69417235T2 (de) | IMIDAZO[1,2-a]PYRAZIN-4-ON-DERIVATE ANTAGONISTEN DER AMPA UND NMDA REZEPTOREN | |
| DE69330754T2 (de) | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN | |
| DE60204044T2 (de) | Piperazin derivate mit sst1 antagonistischer wirkung | |
| DE69208604T2 (de) | Imidazol-Verbindungen, ihre Herstellung und Verwendung als Calcium-Kanal Blocker | |
| DE69130192T2 (de) | Benzimidazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE69318563T2 (de) | 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATE, IHRE HERSTELLUNG UND DIE SIE ENTHALTENDEN ARZNEIMITTEL | |
| DE3788612T2 (de) | Chinoxalin-Verbindungen und deren Herstellung und Verwendung. | |
| DD286581A5 (de) | Verfahren zur herstellung von hetera-aliphatischem carbonsaeureamiden | |
| DE69720021T2 (de) | 1,4-disubstituierte piperazine | |
| DE69201141T2 (de) | NMDA-Antagonisten. | |
| DE69011013T2 (de) | 1-(Pyridinylamino)-2-pyrrolidinone, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |